Gilead(GILD)
Search documents
GILD vs. VRTX: Which Stock Should Value Investors Buy Now?
ZACKS· 2024-11-29 17:46
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies with positive estimate revision trends, and our St ...
Gilead Sciences, Inc. (GILD) Jefferies London Healthcare Conference (Transcript)
2024-11-20 16:45
Gilead Sciences, Inc. (NASDAQ:GILD) 2024 Jefferies London Healthcare Conference November 20, 2024 4:30 AM ET Company Participants Dan O’Day - Chairman and CEO Andy Dickinson - CFO Conference Call Participants Michael Yee - Jefferies Michael Yee I’m Michael Yee, senior biotechnology analyst at Jefferies. And very pleased to have up on the front of this stage here with us the management team from Gilead. On my right, we have the Chairman and CEO, Dan O’Day; as well as the CFO, Andy Dickinson. I would just lo ...
Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease
Benzinga· 2024-11-15 19:14
On Friday, Gilead Sciences, Inc. GILD revealed data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study evaluating the long-term efficacy and safety of Livdelzi.The study showed that 81% (30 out of 37) of participants with primary biliary cholangitis (PBC) treated with Livdelzi (seladelpar) achieved a composite biochemical response (CBR), demonstrating significant improvements in a key measures of PBC progression.Additionally, 41% (15 out of 37) of participants achieved normali ...
Brokers Suggest Investing in Gilead (GILD): Read This Before Placing a Bet
ZACKS· 2024-11-14 15:30
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?Let's take a look at what these Wall Street heavyweights have to say about Gilead Sciences (GILD) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Gilead currently has an average brokerage recommendation ...
GILD or VRTX: Which Is the Better Value Stock Right Now?
ZACKS· 2024-11-12 17:45
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Gilead Sciences (GILD) or Vertex Pharmaceuticals (VRTX) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank is a proven stra ...
Gilead(GILD) - 2024 Q3 - Quarterly Report
2024-11-12 13:36
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value, $0.001 per share GILD The Nasdaq Global Select Market FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ ...
Gilead Sciences: Finally Some Real Momentum
Seeking Alpha· 2024-11-08 21:44
If you like to see more ideas, please subscribe to the premium service "Value in Corporate Events" here and try the free trial. In this service we cover major earnings events, M&A, IPOs and other significant corporate events with actionable ideas. Furthermore, we provide coverage of situations and names on request!As the leader of the investing group Value In Corporate Events they provide members with opportunities to capitalize on IPOs, mergers & acquisitions, earnings reports and changes in corporate capi ...
Gilead Beats on Q3 Earnings and Sales, Raises Annual Outlook
ZACKS· 2024-11-07 17:15
Gilead Sciences, Inc. (GILD) reported better-than-expected third-quarter results and raised its annual earnings guidance.Adjusted earnings per share (EPS) of $2.02 beat the Zacks Consensus Estimate of $1.58. In the year-ago quarter, the company reported adjusted earnings of $2.29 per share.The year-over-year decrease was due to higher acquired IPR&D and tax expenses.Total revenues of $7.5 billion beat the Zacks Consensus Estimate of $7 billion. Revenues also increased 7% year over year, primarily due to hig ...
Gilead's Stock Surge: What's Fueling the Momentum?
MarketBeat· 2024-11-07 17:09
Gilead Sciences Today | --- | --- | |---------------------------|-------| | | | | | | | | | | GILD Gilead Sciences | | | $97.09 +5.40 (+5.89%) | | | 52-Week Range $62.07 | | | ▼ | | | $98.31 | | | | | | Dividend Yield 3.17% | | | P/E Ratio | | | 118.40 | | | Price Target | | | $88.65 | | | | | Add to Watchlist Gilead Sciences NASDAQ: GILD recently broke its 52-week high and is up over 40% over the past six months. As a leading biopharmaceutical company dedicated to pioneering innovative therapies, Gilead bo ...
Why Gilead's Solid Q3 Earnings Could Point To A Dividend Surprise Next Year
Seeking Alpha· 2024-11-07 13:40
Analyst’s Disclosure: I/we have a beneficial long position in the shares of GILD either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. The contents of this article, my previous articles, and my comments are for informational purposes only and may not be considered investment a ...